

Table 13.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1999 to 2008
Recipients with Heart-Lung Transplants

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Transplants	51	48	27	33	29	40	35	31	31	27
Tx with Antirejection Treatments	18	16	4	8	8	12	10	13	6	6
Antibodies										
Any in Category	5.6%	18.8%	0.0%	0.0%	12.5%	16.7%	0.0%	38.5%	0.0%	16.7%
Atgam/NRATG/NRATS	0.0%	6.3%	0.0%	0.0%	12.5%	0.0%	0.0%	15.4%	0.0%	0.0%
Thymoglobulin	5.6%	0.0%	0.0%	0.0%	0.0%	16.7%	0.0%	15.4%	0.0%	16.7%
Zenapax	0.0%	12.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.7%	0.0%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.7%	0.0%	0.0%
Corticosteroids										
Any in Category	94.4%	93.8%	100.0%	100.0%	62.5%	100.0%	100.0%	100.0%	100.0%	100.0%
Steroids	94.4%	93.8%	100.0%	100.0%	62.5%	100.0%	100.0%	100.0%	100.0%	100.0%
Antimetabolites										
Any in Category	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.